Press Releases

Title

View

Date

Sept 6, 2017

NeuroRx awarded FDA Fast Track Designation for first drug regimen targeting suicide in bipolar depression

May 22, 2017

NeuroRx announces initiation of Israel-based Phase 3 research for treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression

Apr 12, 2017

NeuroRx Partners with Leading Patient Advocacy Groups and Experts in the Bipolar Disorder Community to Launch 1st Global “Voice of the Patient” Survey to Gain Insights into Care Received during Hospitalization for a Suicidal Crisis

Mar 24, 2017

NeuroRx to Take Part in Panel and Present at the Sachs Associates Neuroscience Biopartnering & Investment Forum on March 27th

Mar 20, 2017

NeuroRx to Present at the Oppenheimer Annual Healthcare Conference on March 21st

 

Feb 10, 2017

NeuroRx to Present at the BIO CEO & Investor Conference on February 13

NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data

Jan 4, 2017

NeuroRx Solidifies Intellectual Property Position - receives notice of Allowance by US Patent Office

Oct 18, 2016

NeuroRx Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13, 2016

Sept 7, 2016

NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition

June 1, 2016

NeuroRx Provides Clinical Development Update for Cyclurad™,

a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder

American Psychiatric Association Task Force Report Identifies

Potential Value of NeuroRx Active Ingredient for Treatment of

Depression

NeuroRx Announces First Human Trial Results Targeting

Sustained Treatment of Bipolar Depression & Suicidality

December 16, 2015

October 21, 2015

June 24, 2015

© 2016 NeuroRx, Inc.

*This drug is investigational and not approved by the US FDA

STAY CONNECTED